---
title: "Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275509377.md"
datetime: "2026-02-10T21:03:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275509377.md)
  - [en](https://longbridge.com/en/news/275509377.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275509377.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275509377.md) | [English](https://longbridge.com/en/news/275509377.md)


# Incyte posts FY cash provided by operating activities of USD 1.41 billion, up 321%

Incyte Corporation reported its financial results for the full year ended December 31, 2025. The company disclosed cash, cash equivalents, and marketable securities totaling USD 3.58 billion as of December 31, 2025, with working capital at USD 3.51 billion. Cash provided by operating activities for the year was USD 1.41 billion. Net interest income for the period was USD 105.6 million, reflecting a decrease due to a lower interest rate environment compared to the previous year. In terms of equity investments, Incyte recorded a gain of USD 11.1 million from its investment in Syndax for the year. Capital expenditures totaled USD 58.9 million. The company highlighted its ongoing global operations, with headquarters in Wilmington, Delaware, and additional commercial and clinical development activities in Europe, Japan, and Canada. No further product or business updates were provided in this earnings release. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879169-26-000010), on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [Syndax Pharma (SNDX.US)](https://longbridge.com/zh-HK/quote/SNDX.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Incyte (INCY.US)](https://longbridge.com/zh-HK/quote/INCY.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)

## 相關資訊與研究

- [Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer](https://longbridge.com/zh-HK/news/281516898.md)
- [Incyte's skin disease drug shows long-term symptom relief in late-stage trials](https://longbridge.com/zh-HK/news/280886206.md)
- [Insights into Syndax Pharmaceuticals Q4 Earnings](https://longbridge.com/zh-HK/news/277096776.md)
- [Telomir seeks FDA approval for Telomir-1 to treat breast cancer](https://longbridge.com/zh-HK/news/281346305.md)
- [Telomir submits IND for Telomir-1 to treat advanced and metastatic TNBC](https://longbridge.com/zh-HK/news/281174396.md)